CCDS Questions Bank

For an inpatient discharge, a diagnosis documented as “probable” may be coded as though the condition existed or was established when it remains documented as such at discharge.

The FY 2026 ICD-10-CM Official Guidelines provide a specific inpatient rule for uncertain diagnoses documented at the time of discharge. Terms such as probable, suspected, likely, questionable, possible, still to be ruled out, compatible with, and consistent with are coded as if the condition existed, because the diagnostic workup and treatment generally correspond to the suspected condition.

Therefore, aspiration pneumonia—not merely the respiratory symptoms—is the appropriate condition to code in this scenario.

This rule is specific to inpatient hospital coding and should not be generalized to outpatient encounters, where uncertain diagnoses are handled differently and symptoms or confirmed conditions are generally reported instead.

A query would still be appropriate if the documentation were contradictory, clinically ambiguous, or if multiple competing diagnoses remained without sufficient clarification. But the word “probable” itself does not create a mandatory inpatient query.

CCDS Reference Topics: Inpatient uncertain diagnoses; aspiration pneumonia; discharge documentation; Official Guidelines.

=========

Megestrol acetate is the correct choice. This item is adapted from an official ACDIS CCDS sample question in the Candidate Handbook, where Megace—megestrol acetate—is identified as the appropriate appetite-stimulating medication.

Megestrol acetate is a synthetic progestational agent with recognized appetite-stimulating effects. Current U.S. prescribing information specifically identifies megestrol acetate oral suspension for anorexia, cachexia, or significant unexplained weight loss in patients with AIDS. Its use illustrates why CDI specialists need functional knowledge of pharmacology: medication profiles can provide clinically relevant clues to diagnoses under evaluation, although a medication alone never establishes a reportable diagnosis.

Memantine is primarily used in Alzheimer's disease and is not an appetite stimulant. Levothyroxine replaces thyroid hormone in hypothyroidism. Sibutramine was historically used for weight reduction rather than cachexia and is therefore directionally opposite to the desired effect.

In CDI review, identification of megestrol may prompt assessment of the record for malnutrition, cachexia, malignancy-related weight loss, HIV-associated wasting, or another underlying cause, but the provider must document the diagnosis.

CCDS Reference Topics: Pharmacology; cachexia; nutrition disorders; clinical indicators.

=========

The high-risk practice is destroying unanswered queries. Query retention should be governed by an established organizational policy and should not depend on whether the provider answers the query. Selectively destroying unanswered queries can create significant compliance, audit, and record-integrity concerns because it removes evidence of the documentation-clarification process.

ACDIS/AHIMA guidance has consistently required organizations to establish query-retention policies. Queries may be retained as part of the permanent health record or maintained as a retrievable business record according to organizational policy and legal requirements. The current 2026 ACDIS/AHIMA query practice guidance supersedes all previous editions, reinforcing the importance of a standardized, defensible query process.

Keeping queries in the health record is not inherently problematic when policy defines them as part of that record. Likewise, a new diagnosis may be included in a multiple-choice query when it is supported by patient-specific clinical indicators and the choices remain nonleading. A yes/no query can also be compliant in defined circumstances, such as clarification of a diagnosis or relationship already documented.

Selective destruction is therefore the clear compliance risk.

CCDS Reference Topics: Query retention; compliance; organizational query policy; audit integrity.

=========

The most clinically supported clarification is acute cerebral infarction. A transient ischemic attack is characterized by transient neurologic dysfunction without acute infarction. In this scenario, the patient's slurred speech has resolved, but the right-sided weakness persists, and CT demonstrates a new hypodense cerebral area. Together, those findings raise substantial concern for an established ischemic infarction rather than a completely transient event.

The CDI specialist should not independently convert the diagnosis of TIA to cerebral infarction. Instead, the persistent focal deficit and imaging findings establish an appropriate clinical basis for a provider query asking whether the final diagnosis is acute cerebral infarction, TIA, another neurologic condition, or clinically undetermined.

Acute encephalopathy generally produces global cerebral dysfunction rather than the focal unilateral weakness described here. Transient global amnesia predominantly affects memory formation and would not explain persistent unilateral motor deficits. Transient cerebral ischemia/TIA becomes less consistent once objective evidence of acute infarction and persistent neurologic impairment is present.

Accurate clarification is important because cerebral infarction and TIA differ substantially in coding, severity representation, quality reporting, and secondary-prevention planning.

CCDS Reference Topics: Neurologic clinical indicators; cerebral infarction versus TIA; diagnostic clarification; medical record specificity.

=========